The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy, safety and pharmacokinetics (PK) of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients (pts) with NTRK fusion-positive (NTRK+) solid tumors.
 
Yizhuo Zhang
No Relationships to Disclose
 
Huanmin Wang
No Relationships to Disclose
 
Yeming Wu
No Relationships to Disclose
 
Suying Lu
No Relationships to Disclose
 
Junting Huang
No Relationships to Disclose
 
Jia Zhu
No Relationships to Disclose
 
Feifei Sun
No Relationships to Disclose
 
Juan Wang
No Relationships to Disclose
 
Wei Yang
No Relationships to Disclose
 
Zhixiang Wu
No Relationships to Disclose
 
Jie Gao
Employment - Beijing InnoCare Pharma Tech
Stock and Other Ownership Interests - Beijing InnoCare Pharma Tech
 
Xuan Pu
Employment - Beijing InnoCare Pharma Tech
 
Sizhe Chen
Employment - Beijing InnoCare Pharma Tech
 
Xin Liu
Employment - Beijing InnoCare Pharma Tech
 
Yuhan Shan
Employment - Beijing InnoCare Pharma Tech
 
Tong Li
Employment - Beijing InnoCare Pharma Tech
 
Bin Zhang
Employment - Beijing InnoCare Pharma Tech
Stock and Other Ownership Interests - Beijing InnoCare Pharma Tech
 
Renbin Zhao
Employment - Beijing InnoCare Pharma Tech
Leadership - Beijing InnoCare Pharma Tech
Stock and Other Ownership Interests - Beijing InnoCare Pharma Tech
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Hutchison MediPharma; Junshi Pharmaceuticals; Keymed Biosience; MSD; QiLu Pharmaceutical